FibroGen Inc (NASDAQ:FGEN) – Leerink Swann cut their Q3 2018 earnings per share estimates for FibroGen in a research note issued to investors on Monday, October 15th. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter, down from their prior forecast of ($0.27). Leerink Swann has a “Buy” rating and a $84.00 price target on the stock. Leerink Swann also issued estimates for FibroGen’s Q4 2018 earnings at $0.24 EPS, FY2018 earnings at ($0.82) EPS, FY2019 earnings at ($0.16) EPS, FY2020 earnings at $0.89 EPS, FY2021 earnings at ($0.16) EPS and FY2022 earnings at $1.87 EPS.

Other research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a research note on Wednesday. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 9th. ValuEngine downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Mizuho reissued a “buy” rating and set a $74.00 price target on shares of FibroGen in a research note on Wednesday, August 8th. Finally, Citigroup downgraded shares of FibroGen from a “buy” rating to a “hold” rating and set a $71.00 price target on the stock. in a research note on Wednesday, August 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. FibroGen presently has a consensus rating of “Buy” and an average price target of $72.25.

FGEN stock opened at $54.63 on Wednesday. The company has a market cap of $5.12 billion, a price-to-earnings ratio of -31.58 and a beta of 1.81. FibroGen has a one year low of $40.74 and a one year high of $68.55. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.19.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.31. The firm had revenue of $43.95 million for the quarter, compared to the consensus estimate of $28.70 million. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%.

In related news, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction on Friday, September 7th. The shares were sold at an average price of $56.75, for a total value of $1,072,575.00. Following the transaction, the chief executive officer now directly owns 2,761,894 shares of the company’s stock, valued at $156,737,484.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $63.00, for a total transaction of $2,497,068.00. Following the completion of the transaction, the chief executive officer now directly owns 2,804,873 shares in the company, valued at $176,706,999. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 213,773 shares of company stock worth $12,753,794. 8.96% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of FibroGen by 23.8% in the second quarter. FMR LLC now owns 8,463,528 shares of the biopharmaceutical company’s stock worth $529,817,000 after buying an additional 1,624,749 shares during the period. BlackRock Inc. increased its stake in shares of FibroGen by 4.6% in the second quarter. BlackRock Inc. now owns 6,182,657 shares of the biopharmaceutical company’s stock worth $387,037,000 after buying an additional 271,981 shares during the period. Hillhouse Capital Management Ltd. increased its stake in shares of FibroGen by 3.2% in the second quarter. Hillhouse Capital Management Ltd. now owns 2,686,196 shares of the biopharmaceutical company’s stock worth $168,156,000 after buying an additional 83,850 shares during the period. First Trust Advisors LP boosted its holdings in FibroGen by 19.4% in the second quarter. First Trust Advisors LP now owns 1,198,925 shares of the biopharmaceutical company’s stock valued at $75,053,000 after acquiring an additional 194,766 shares in the last quarter. Finally, Eagle Asset Management Inc. boosted its holdings in FibroGen by 18.5% in the second quarter. Eagle Asset Management Inc. now owns 971,694 shares of the biopharmaceutical company’s stock valued at $60,828,000 after acquiring an additional 151,574 shares in the last quarter. 76.06% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Recommended Story: Find a Trading Strategy That Works

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.